Search Results for keywords:"DEA"

The Stepan Company has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of certain controlled substances, as per the notice from the Justice Department's DEA. The application is to import these substances to manufacture other controlled substances, but not for commercial sale in finished form. Interested parties, such as current manufacturers or applicants, can comment or request a hearing about this application until April 9, 2025. Comments and hearing requests should be submitted through specified DEA addresses or electronically via the Federal eRulemaking Portal.

The Indigenous Peyote Conservation Initiative has applied to the Drug Enforcement Administration (DEA) to become registered as an importer of certain controlled substances, specifically Peyote plants. They aim to use the imported Peyote for research, analysis, and conservation efforts related to South Texas Cacti. Public comments or objections to this application can be submitted until March 1, 2021, and requests for a hearing must also be made by then. The DEA will grant the registration only if the applicant's activities comply with authorized guidelines, and it does not include commercial importation of finished drug forms.

The Drug Enforcement Administration (DEA) has announced that GGGYI LLC has applied to be registered as a bulk manufacturer of certain controlled substances, specifically marihuana, for research purposes. This application is part of DEA's program to oversee the cultivation and distribution of marihuana for scientific and medical research under strict regulations. Interested parties, such as existing manufacturers or applicants, can submit comments or objections regarding this application by April 26, 2021. The DEA will evaluate the application based on applicable laws and regulations to ensure proper safeguards against misuse are in place.

Chattem Chemicals has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of controlled substances. The application, filed on July 20, 2020, lists substances like Marihuana and Tetrahydrocannabinols, which the company plans to create synthetically for distribution and sale. Interested parties can submit comments or request a hearing on this application by April 26, 2021. Written comments should be sent to the DEA in Springfield, Virginia.

Meridian Medical Technologies, LLC has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances. The company plans to import these substances solely for analytical purposes and has no authorization for other activities involving these drugs. The DEA is accepting public comments or objections to this application until April 14, 2025, and has outlined procedures for submitting these electronically via regulations.gov. Requests for a hearing regarding the application must also be submitted by the same date to designated DEA offices in Springfield, Virginia.

SpecGx LLC has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances. The company aims to import these substances for the purpose of manufacturing Active Pharmaceutical Ingredients, which will then be distributed to its customers. However, this registration does not automatically allow for permit applications to import these substances to be approved; approval will be granted only if the business activities comply with specific legal requirements. Public comments or requests for a hearing regarding this application are open until April 28, 2025, and can be submitted electronically through the Federal eRulemaking Portal.

The Department of Justice, specifically the Drug Enforcement Administration (DEA), is requesting public feedback on a proposed information collection related to emergency medical services and controlled substances. This proposal aims to ensure compliance with the Controlled Substances Act by setting new recordkeeping standards for emergency medical services agencies. These standards involve maintaining records of controlled substances used by these agencies, which include details about administration, disposal, and delivery. The DEA encourages comments on the necessity, burden, and clarity of this information collection until January 13, 2025, as part of their efforts to secure approval for a three-year authorization under the Paperwork Reduction Act.

Mylan Pharmaceuticals, Inc. has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of basic classes of controlled substances. Interested parties, such as registered bulk manufacturers, can submit electronic comments or objections about this application by March 20, 2025, or request a hearing. Comments should be submitted through the Federal eRulemaking Portal, and requests for a hearing should be sent to the DEA's specified addresses. Mylan Pharmaceuticals seeks authorization to import controlled substances in finished dosage form for commercial distribution, with certain restrictions aligning with legal requirements.

Leading Pharma LLC has applied to register as an importer of controlled substances. This application is for research and development purposes, aiming toward creating a new pharmaceutical product that is pending approval by the Food and Drug Administration (FDA). Interested parties can submit comments or request a hearing regarding this application, with a deadline of January 17, 2025. The Drug Enforcement Administration (DEA) will approve the application only if it meets specific legal criteria.

Vici Health Sciences, LLC has applied to become an importer of specific controlled substances to support their research and clinical trials. The Drug Enforcement Administration (DEA) is accepting public comments and objections to this application until February 27, 2025. Interested parties can submit their comments electronically through the Federal eRulemaking Portal. The DEA has specified that this permit will not authorize the import of finished medication forms for sale.